Healthcare Bullish Movers: Organovo Holdings (NYSEMKT:ONVO), Harvard Bioscience (NASDAQ:HBIO), Nature’s Sunshine Prod. (NASDAQ:NATR), Ruthigen (NASDAQ:RTGN), QLT (NASDAQ:QLTI)

In company news, Organovo Holdings ( ONVO ) advanced Thursday, with shares of the artificial-tissues company climbing as much as 12% after saying the head of mechanistic safety at Roche Holding AG ( RHHBY ) was able to distinguish a toxic drug known to cause liver injury from a similar but non-toxic compound using ONVO’s 3D human liver tissues. Organovo Holdings Inc (NYSEMKT:ONVO) stock performance was 11.72% in last session and finished the day at $8.20. Traded volume was 4.39million shares in the last session and the average volume of the stock remained 1.40million shares. Organovo Holdings Inc (NYSEMKT:ONVO) insider ownership is 8.60%.

Harvard Bioscience, Inc. (NASDAQ:HBIO) surged nearly 8 percent in the current trading session after Janney Capital Markets issued a “Buy” rating for the company in a research report released yesterday. Harvard Bioscience, Inc. (NASDAQ:HBIO) rose 5.36 percent to $3.93 Thursday on volume of 763,878.00million shares. The intra-day range of the stock was $3.86 to $4.10. Harvard Bioscience, Inc. (NASDAQ:HBIO) has a market capitalization of $125.59million.

Nature’s Sunshine enters China, the fastest growing direct selling market in the world, with local strategic partner . Companies will form a joint venture to market and distribute Nature’s Sunshine and Synergy products in China through an innovative multi-channel approach. Nature’s Sunshine Prod. (NASDAQ:NATR)’s stock on June 26, 2014 reported a increase of 6.64% to the closing price of $16.71. Its fifty two weeks range is $12.91 -$20.15. The total market capitalization recorded $270.35million. The overall volume in the last trading session was 145,908.00million shares. In its share capital, NATR has 16.18million outstanding shares.

The US Food and Drug Administration (FDA) has cleared Ruthigen Inc’s Investigational New Drug (IND) application without a clinical hold to begin human clinical testing of RUT58-60. On Thursday, shares of Ruthigen Inc (NASDAQ:RTGN) advanced 6.24% to close the day at $6.47. Company monthly performance is recorded as 6.77%. Ruthigen Inc (NASDAQ:RTGN) quarterly revenue growth is -4.15%.

QLT Inc. (QLT.TO) soared 13.62 percent after signing a definitive agreement to merge itself with Auxilium Pharmaceuticals Inc. (AUXL), a fully integrated specialty biopharmaceutical company. QLT Inc. (USA) (NASDAQ:QLTI) stock performance was 14.64% in last session and finished the day at $6.19. Traded volume was 3.49million shares in the last session and the average volume of the stock remained 36.33K shares. The beta of the stock remained 0.80. QLT Inc. (USA) (NASDAQ:QLTI) insider ownership is 0.50%.